SPECTRACEF
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SPECTRACEF (SPECTRACEF).
Cefditoren, a third-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
| Metabolism | Cefditoren pivoxil (prodrug) is hydrolyzed to cefditoren by esterases; cefditoren is not significantly metabolized by the liver. Excretion is primarily renal via tubular secretion. |
| Excretion | Renal: 88% as unchanged drug, Fecal: negligible, Biliary: minimal |
| Half-life | Terminal elimination half-life: 2.5 hours (range 2.0-3.0 hours) in healthy adults; prolonged in renal impairment (up to 10 hours in severe impairment) |
| Protein binding | Protein binding: 65-75%, primarily to albumin |
| Volume of Distribution | Volume of distribution: 0.3-0.5 L/kg; indicates distribution primarily into extracellular fluid and tissues |
| Bioavailability | Oral bioavailability: 90-95% (tablet) and 80-90% (oral suspension) |
| Onset of Action | Oral: Rapid absorption; peak serum concentrations at 2-3 hours; clinical effect within 24-48 hours for most infections |
| Duration of Action | Duration: 12 hours (bactericidal levels persist); dosing every 12 hours for most indications |
| Molecular Weight | 506.57 Da |
400 mg orally twice daily for 10-14 days.
| Dosage form | TABLET |
| Renal impairment | CrCl 30-49 mL/min: 200 mg twice daily; CrCl 15-29 mL/min: 200 mg every 24 hours; CrCl <15 mL/min or hemodialysis: 200 mg every 24 hours. |
| Liver impairment | No specific adjustment recommended for mild to moderate hepatic impairment; contraindicated in severe hepatic impairment (Child-Pugh C) due to lack of data. |
| Pediatric use | For patients 12 years and older: 400 mg twice daily. Safety and efficacy in patients under 12 years not established. |
| Geriatric use | Adjust dose based on renal function; elderly patients are more likely to have decreased renal function, so monitor CrCl and adjust accordingly. |
| 1st trimester | Avoid use during first trimester unless no alternative; animal studies show some evidence of risk. |
| 2nd trimester | Use with caution if clearly needed; no well-controlled human studies, but potential benefit may warrant use. |
| 3rd trimester | Use with caution; avoid near term due to potential for kernicterus in neonates. |
Clinical note
Comprehensive clinical and safety monograph for SPECTRACEF (SPECTRACEF).
| Placental transfer | Cefditoren crosses the placenta to a limited extent; fetal plasma concentrations are approximately 5-10% of maternal levels. |
| Breastfeeding | Cefditoren is excreted into human milk in small amounts. Use with caution in nursing mothers; consider risk of diarrhea and candidiasis in the infant. |
| Lactation Rating |
■ FDA Black Box Warning
No FDA black box warning is present for this drug.
| Common Effects | Increased heart rate Blurred vision Constipation Difficulty in urination Dryness in mouth Orthostatic hypotension sudden lowering of blood pressure on standing Weight gain |
| Serious Effects |
Hypersensitivity to cefditoren or any cephalosporin antibioticHypersensitivity to penicillin (potential cross-reactivity)Carnitine deficiency or inborn errors of metabolism affecting carnitine (cefditoren pivoxil contains a pivalate moiety that can reduce carnitine levels)
| Precautions | Hypersensitivity reactions, including anaphylaxis, particularly in patients with penicillin allergy, Clostridium difficile-associated diarrhea (CDAD), Risk of bleeding with vitamin K deficiency or anticoagulant use due to reduction of vitamin K-producing gut flora, Renal impairment: dose adjustment required for CrCl <50 mL/min, Potential for false-positive urinary glucose tests (Clinitest) and direct Coombs test |
Loading safety data…
| L2 (Probably Compatible) |
| Teratogenic Risk | Insufficient human data; animal studies show no evidence of fetal harm at clinically relevant doses. Generally considered low risk; avoid in first trimester unless necessary. |
| Fetal Monitoring | No specific monitoring required; standard prenatal care. |
| Fertility Effects | No known adverse effects on fertility in animal studies. |
| Food/Dietary |
| Take with a full meal (preferably high-fat) to enhance absorption. Avoid grapefruit juice as it may affect drug metabolism. Avoid antacids containing magnesium or aluminum, and iron supplements; take at least 2 hours apart. |
| Clinical Pearls | Cefditoren pivoxil (Spectracef) is a third-generation cephalosporin with enhanced activity against Gram-positive and Gram-negative bacteria, including penicillin-resistant Streptococcus pneumoniae. It is pro-drug that requires ester hydrolysis for activation; administer with meals to increase absorption and reduce GI intolerance. Renal dosing adjustments are necessary: CrCl 30-49 mL/min: 200 mg BID; CrCl <30 mL/min or hemodialysis: 200 mg QD. Monitor for potential prothrombin time prolongation, especially in patients with renal or hepatic impairment due to vitamin K deficiency. Avoid in patients with carnitine deficiency or those on valproic acid due to risk of carnitine depletion. |
| Patient Advice | Take this medication exactly as prescribed, usually twice daily with food to improve absorption and reduce stomach upset. · Complete the full course of therapy even if you feel better; stopping early may lead to resistant bacteria. · This drug may cause diarrhea, including a severe form (Clostridioides difficile infection). Contact your doctor if you develop watery or bloody stools. · If you have kidney problems, your dose may need adjustment; adhere to your lab monitoring schedule. · Notify your provider if you have a history of allergic reactions to penicillins or cephalosporins; cross-reactivity may occur. · Do not take with antacids containing magnesium or aluminum, or with iron supplements; separate by at least 2 hours. · Report any signs of bleeding (easy bruising, prolonged bleeding) or symptoms of carnitine deficiency (muscle pain, confusion). |